Fig. 3.

Adjusted survival probability estimates of mAEFS, rwPFS, and OS for alectinib and crizotinib using the Cox proportional hazard models. The adjusted survival probability estimates of a major-adverse-event-free survival, b real-world progression-free survival, and c overall survival for 117 assessable patients are shown. The adjusted survival probabilities shown were estimates of a typical patient with covariates corresponding to the most common category for categorical features and the mean for continuous features. The x-axis shows months since the initiation of the first ALK TKI treatment. Abbreviations: mAEFS: major-adverse-event-free survival, rwPFS: real-world progression-free survival, OS: overall survival